NOTE
🌱 created from: nccn_flowchart_of_mantle_cell_lymphoma
triangle_regimen
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE):
- a three-arm,
- randomised,
- open-label,
- phase 3 superiority trial
- of the European Mantle Cell Lymphoma Network
Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. The Lancet. 2024;403(10441):2293-2306. doi:10.1016/S0140-6736(24)00184-3